Bausch + Lomb, Corporation
https://www.bausch.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bausch + Lomb, Corporation
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
Bausch + Lomb Patiently 'Semi-Private' While Bausch Health Plots Path To Spin-Out Completion
B+L using period of Bausch Health’s near-full ownership to plan for future. "When the spin comes, then we can spend a lot more time with our investors. But right now, I just have to take the elevator down two floors and I can see the 90% shareholder,” says CEO Brent Saunders.
US Health And Wellness Executive Decisions: Herbalife, Bausch + Lomb, Cascadia Capital
Herbalife distributor leaves board to be strategy chief; Bausch + Lomb increases executive posts; and Cascadia Capital director’s focus includes sports nutrition.
Consumer Health Brands Pull Their Weight For Bausch + Lomb To Be ‘Non-Pharma’ Company
Canadian reports Lumify eye, PreserVision, Ocuvite and other OTC drug or supplement brands account for 67% of $646m in vision care business total sales, which was well above half Q2 total revenues of $1.04bn, up 10%.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice